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ABSTRACT 
Acute, ascending, flaccid motor paralysis of forelimbs and death due to respiratory failure 
is the dominant characteristic of tick toxicosis by the Australian paralysis tick, Ixodes 
holocyclus. A tick toxin vaccine has the potential to be an effective preventative measure 
against tick toxicosis that affects thousands of domestic and companion animals each year. 
In previous research for the development of an anti-tick vaccine, Masina (1999) used a 
maltose-binding protein (MBP) holocyclus toxin (HT-1) fusion protein as immunogen. It 
was partially protective against challenges with crude tick extract in neonatal mice but 
unable to protect dogs against paralysis caused by direct tick attachment. 
Subsequently, four monoclonal antibodies generated in this study against the fusion protein 
were found to be incapable of binding to the native toxin in crude tick extract in Western 
blots. These results indicated that the HT -1 component of the MBP fusion protein was 
incorrectly folded compared to the native toxin. 
An expressiOn system usmg ubiquitin fusion protein was investigated. Ubiquitin is a 
10 kDa carrier protein which is smaller than the 43 kDa MBP. A smaller fusion partner was 
considered as it is less likely to interfere with HT-1 folding. The ubiquitin-HT-1 fusion 
protein was expressed in both soluble and insoluble forms, corresponding to the 
cytoplasmic fraction and inclusion bodies. The soluble form could be purified under 
non-denaturing conditions utilising the incorporated His-6-tag and a Ni affinity column. 
The insoluble form, like the periplasmically expressed MBP-HT-1 fusion protein, could 
only be purified using denaturing conditions. 
The purified soluble ubiquitin-HT-1 fusion protein appeared to have the correct 
conformational folding as it was recognized by commercial dog anti-tick serum in Western 
blots. The purified soluble ubiquitin-HT-1 fusion protein was used to immunise rabbits and 
mice for protection experiments, but was found to be unprotective. However, serum from 
immunized animals was able to detect a 5 kDa protein from crude tick extract in a Western 
blot. This 5 kDa protein was also recognized by the commercial dog anti-tick serum and 
xii 
has the molecular weight corresponding to the HT -1 neurotoxin. Creation of monoclonal 
antibodies to this ubiquitin-HT-1 fusion protein may therefore aid future development 
towards a tick vaccine. These antibodies could in turn be used to isolate native HT -1 from 
the crude tick extract instead of a combination of conventional chromatography methods. 
This approach would allow isolation of HT -1 in more significant quantities than is currently 
possible to enable confirmation of the HT -1 sequence. Suspected problems associated with 
incorrect sequence or interference by the carrier protein to cause a non-protective response 
could also be resolved. 
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